Candel Therapeutics (CADL) Equity Average (2021 - 2023)
Historic Equity Average for Candel Therapeutics (CADL) over the last 3 years, with Q3 2023 value amounting to $26.9 million.
- Candel Therapeutics' Equity Average fell 5205.57% to $26.9 million in Q3 2023 from the same period last year, while for Sep 2023 it was $26.9 million, marking a year-over-year decrease of 5205.57%. This contributed to the annual value of $55.9 million for FY2022, which is 17566.48% up from last year.
- According to the latest figures from Q3 2023, Candel Therapeutics' Equity Average is $26.9 million, which was down 5205.57% from $35.2 million recorded in Q2 2023.
- Over the past 5 years, Candel Therapeutics' Equity Average peaked at $63.9 million during Q1 2022, and registered a low of $9.9 million during Q3 2021.
- For the 3-year period, Candel Therapeutics' Equity Average averaged around $45.7 million, with its median value being $49.9 million (2022).
- In the last 5 years, Candel Therapeutics' Equity Average surged by 46631.84% in 2022 and then tumbled by 5205.57% in 2023.
- Quarter analysis of 3 years shows Candel Therapeutics' Equity Average stood at $63.6 million in 2021, then dropped by 21.46% to $49.9 million in 2022, then plummeted by 46.12% to $26.9 million in 2023.
- Its Equity Average stands at $26.9 million for Q3 2023, versus $35.2 million for Q2 2023 and $43.7 million for Q1 2023.